Recent advances in the roles of exosomal microRNAs (exomiRs) in hematologic neoplasms: pathogenesis, diagnosis, and treatment [PDF]
Cell Communication and Signaling, 2023 In clinical diagnosis, the capability of exosomes to serve as biomarkers is one of the most important biological functions of exosomes. The superior stability of exosome biomarkers makes them superior to those isolated from traditional samples such as ...
Faride Nam Avar Jahromi +2 more
doaj +2 more sources
Autoimmune Complications in Hematologic Neoplasms. [PDF]
Cancers (Basel), 2021 Autoimmune cytopenias (AICy) and autoimmune diseases (AID) can complicate both lymphoid and myeloid neoplasms, and often represent a diagnostic and therapeutic challenge. While autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) are well known, other rarer AICy (autoimmune neutropenia, aplastic anemia, and pure red cell aplasia) and ...
Barcellini W, Giannotta JA, Fattizzo B.
europepmc +4 more sources
Association of hydralazine use with risk of hematologic neoplasms in patients with hypertension: A nationwide population-based cohort study in Taiwan. [PDF]
PLoS MedicineBackgroundOnco-hypertension recognizes well-controlled blood pressure as a favorable prognostic factor for survival in patients with hypertension and solid tumors, including hematologic neoplasms.
Li-Tzu Wang +6 more
doaj +2 more sources
Care for patients with hematologic neoplasms: contextual analysis resulting from a scoping review [PDF]
Revista Brasileira de EnfermagemObjective: To analyze and map evidence in the literature on the contexts in which care for patients with hematologic neoplasms occurs within health services.
Isabelle Campos de Azevedo +5 more
doaj +2 more sources
Dermatological manifestations of hematologic neoplasms. Part I: secondary specific skin lesions [PDF]
Anais Brasileiros de Dermatologia, 2023 Cutaneous manifestations occur during the course of hematologic malignancies and precede, follow, or are late events in relation to the diagnosis. They result from paraneoplastic phenomena, tumor infiltrations, and immunosuppression resulting from the ...
Patricia Karla de Souza +3 more
doaj +2 more sources
A potential prognostic marker for hematologic neoplasms: CD58 [PDF]
Frontiers in OncologyCD58 is a glycoprotein receptor widely distributed on histiocytes that binds to CD2, that takes part in constituting the Immunological Synapses (IS) and activating T/NK cells.
Jiajia Cao +5 more
doaj +2 more sources
Blastic plasmacytoid dendritic cell neoplasm secondary to acute myeloid leukemia with shared mutations in TET2 and DNMT3A: a case report and literature review [PDF]
Frontiers in ImmunologyBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. Recent studies have highlighted its occurrence in patients with a history of preceding myeloid neoplasms.
Yao Sun +5 more
doaj +2 more sources
Frontiers in Immunology, 2022 The outcomes of 80 patients with hematologic malignancies who received haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) combined with unrelated cord blood (UCB) from March 2017 to June 2020 were analyzed in this retrospective study.
Cong Zeng +35 more
doaj +1 more source
Hematological Neoplasms with Eosinophilia
Cancers, 2023 Eosinophils in peripheral blood account for 0.3–5% of leukocytes, which is equivalent to 0.05–0.5 × 109/L. A count above 0.5 × 109/L is considered to indicate eosinophilia, while a count equal to or above 1.5 × 109/L is defined as hypereosinophilia. In bone marrow aspirate, eosinophilia is considered when eosinophils make up more than 6% of the total ...
Rosario M. Morales-Camacho +4 more
openaire +3 more sources
Frontiers in Oncology, 2022 Recent studies have shown that haploidentical hematopoietic stem cell transplantation supported by third-party cord blood (haplo-cord-HSCT) results in rapid hematopoietic recovery, low incidences of graft-versus-host disease (GVHD), and relapse of ...
Tingting Cheng +31 more
doaj +1 more source